Science

FDA rejects Capricor Duchenne therapy, a decision that was a long time coming

FDA rejects Capricor Duchenne therapy, a decision that was a long time coming


Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

The Food and Drug Administration said Friday that it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics. 

The decision to block the treatment, called deramiocel, from reaching the market should have been an easy one for regulators to make. The targeted patient population — teenagers and young men with Duchenne who had already lost the ability to walk — have few treatment options today. Deramiocel didn’t help them either. Capricor conducted two randomized clinical trials. Both failed to show deramiocel could stave off heart failure or preserve muscle function in their arms. 

But nothing is straightforward when it comes to regulating drugs for Duchenne, a progressive, muscle-wasting disease. 

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe



Source link